Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: BIOLOGICAL: Dendritic Cell (DC1) Vaccine|DRUG: Trastuzumab|DRUG: Pepinemab|BIOLOGICAL: T-Cell therapy
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Vaccinex Inc.